FMP
Cortexyme, Inc.
CRTX
NASDAQ
Inactive Equity
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
1.95 USD
0.05000007 (2.56%)
About
ceo
Ms. Casey Lynch
sector
Healthcare
industry
Biotechnology
website
https://www.cortexyme.comexchange
NASDAQ
Description
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
CIK
0001662774
ISIN
US22053A1079
CUSIP
22053A107
Address
269 E Grand Ave
Phone
14159105717
Country
US
Employee
55
IPO Date
May 9, 2019
Summary
CIK
0001662774
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
22053A107
ISIN
US22053A1079
Country
US
Price
1.95
Beta
1.4
Volume Avg.
0
Market Cap
70.45M
Shares
-
52-Week
-
DCF
4.32
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.66
P/B
-
Website
https://www.cortexyme.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest CRTX News
It looks like there's no news available.
